
Publication: Using the BioAssy Ontology for Analyzing High-Throughput Screening Data
High-throughput screening (HTS) is the main starting point for hit identification in drug discovery programs. This has led to a rapid increase of available screening data both within pharmaceutical companies and the public domain. We have used the BioAssay Ontology (BAO) 2.0 for assay annotation within AstraZeneca to enable comparison…
Open PHACTS poster wins prize at CSHALS 2014 in Boston
Simon Rakov, Linda Zander Balderud and Tom Plasterer from AstraZeneca presented a poster entitled “BAO Reveal: Assay Analysis Using the BioAssay Ontology and Open PHACTS” at the Conference on Semantics in Healthcare and Life Sciences (CSHALS) 2014 in Boston. The poster won the F1000 (Faculty of 1000) Poster Prize, and…
Poster: BAO Reveal: Assay Analysis Using the BioAssay Ontology and Open PHACTS
CSHALS, Conference on Semantics in Healthcare and Life Sciences, Boston, USA Awarded Faculty of 1000 Poster Prize View poster
Conference: 5th Annual aDREAM Conference
5th Development of Robust Experimental Assay Methods (aDREAM) Conference, Madison, USA Linda Zander-Balderud (AstraZeneca) gave a presentation: Applying BioAssay Ontology to facilitate HTS analysis
Presentation: Applying BioAssay Ontology to facilitate HTS analysis
5th Development of Robust Experimental Assay Methods (aDREAM) Conference, Madison, USA Linda Zander-Balderud (AstraZeneca) View presentation